Clinical Trials Browser

Phase 2 × Breast Neoplasms × icotinib × Clear all

NCT02362230 2021-01-29

Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Phase 2 Terminated

Breast Neoplasms